CatSci has made a “significant” investment to support the development of oligonucleotide capability at its site in Cardiff, UK. This follows recent investment in the firm by Keensight Capital to support its strategic growth plans.

Drug development firm CatSci has secured £4.5 million of investment from ‘alternative lender’ Boost & Co. This is described as a continuation of the Cardiff-based firm’s £3 million investment, which was started in 2021.

CatSci will use the funding to install new equipment and expand its laboratories by adding capabilities in chemical and analytical development, material science, product formulation and GMP analytical testing in both Cardiff and London. Some will be used to refinance its existing debt.